Tuesday, November 11, 2008

What's In Your Oil

Once again -

If you follow Natural Health News you know that I am against the use of canola oil in any way, shape or form. You know as well that I have written about the "plant sterol" fiasco that is sweeping the aisles of OTC products that include Centrum Cardio and Bayer's Heart Advantage.

You'll find canola oil in Promise and their "super shots" as well.

Canola is also generally GMO in the market place and it is toxic to your liver.

One expert on fats and oils classes canola oil as "too monounsaturated for health".

Here is a chart and some comments from another natural health advocate that might enlighten you.
7.4% Saturated - 61.6% Monounsaturated - 31.0% Polyunsaturated

Although Canola Oil contains a high percentage of relatively stable monounsaturated fatty acids, canola oil goes rancid quite easily, and relative to olive oil, forms high concentrations of trans fatty acids.

Canola oil consumption has also been linked to vitamin E deficiency and heart disease, especially when a person is not getting enough saturated fatty acids in his or her diet.

I recommend staying away from canola oil whenever possible.

Fertility Concerns

Several new reports show that the effect of supplements can be very helpful when conception and fertility are concerned.

Read the new news notes...

And do remember that your nutritional status has a great impact on your health, especially when planning for a baby.

Low Magnesium, High Blood Pressure

While the original purpose for ADVENTURX was to prevent arm pump in xtreme sports many other benefits have been found during the four years my formula has been available.

Most of us who study natural healing and nutrition already know how magnesium helps reduce blood pressure. Magnesium is nature's ACE inhibitor.

The added benefit of oxygen producing elements in ADVENTURX may be helpful to the process of lowering blood pressure as well.
Evidence that increased reactive oxygen species are link between magnesium deficiency and hypertension
The relationship between high blood pressure and magnesium deficiency has been explored in several studies, producing conflicting evidence. A study published in the November 2002 issue of the Journal of Hypertension submits the hypothesis that insufficient levels of magnesium may lead to hypertension by increasing the formation of reactive oxygen species, harmful molecules that cause oxidative damage.

The University of Montreal researchers divided stroke-prone spontaneously hypertensive rats into three groups that received a control diet containing normal levels of magnesium, a magnesium-free diet and a high magnesium diet, and systolic blood pressure was measured each week for sixteen weeks. In a second experiment, stroke-prone spontaneously hypertensive rats received a control diet, a magnesium-free diet and a magnesium-free diet combined with Tempol, a superoxide dismutase mimetic for seven weeks. Superoxide dismutase is one of the antioxidants naturally produced in the body.

Rats in the low magnesium group experienced an exacerbation in the development of hypertension after five weeks, accompanied by a reduction in oxidative stress markers which increased rapidly after two weeks. The ability of blood vessels to dilate in response to acetylcholine was decreased in the low magnesium group compared to controls. Vessel wall hypertrophy was greater and vascular superoxide higher in the rats who received the magnesium deficient diet compared to those on the high magnesium diet. However, rats on magnesium-free diets receiving Tempol did not experience a progression of hypertension or the vascular changes seen in magnesium deficient rats who did not receive the antioxidant.

In an accompanying editorial, Richard D Bukoski writes that the research provides, "the first link between an essential dietary nutrient and the key molecular pathways involved in regulating vascular smooth muscle growth and structure." (Journal of Hypertension 2002, 20:2141-2143)

Monday, November 10, 2008

Sjogren's Fatigue and Cancer Drugs

UPDATE: 26 January, 2009. Related article.
-----------------------------------------------------
Rituximab is a (monoclonal antibody genetically engineered) drug mainly used as a treatment for Non-Hodgkin's Lymphoma. It may also be used for the treatment of Rheumatoid Arthritis. Now you may receive it if you have fatigue from a thyroid related (generally thought of as auto-immune) dis-order called Sjogren's.

Make sure if this is proposed to you that you get this information that the drug may cause
severe and sometimes fatal infusion reactions. Tell your doctor right away if you develop blurred vision, cough, dizziness, drowsiness, headache, hives, itching, swelling, trouble breathing, or wheezing, while you receive or after you receive Rituximab .

Severe and sometimes fatal kidney problems and skin reactions may also occur during treatment with Rituximab . Tell your doctor right away if you experience decreased urination; red, swollen, peeling, or blistered skin; or skin or mouth sores or ulcers.

Rarely, a severe and sometimes fatal viral infection of the brain has been reported with the use of Rituximab in certain patients. Tell your doctor right away if you notice new or worsening medical problems such as changes in thinking (eg, confusion, disorientation), loss of balance or coordination, muscle weakness, trouble walking or talking, or unusual eye movements or vision changes.


You might also pursue proper thyroid testing, as thyroid dysfunction often is associated with fatigue.

And it now might be related to low levels of vitamin D-
Researchers at UCLA tried to show that low vitamin D would make an autoimmune thyroid problem worse. Their experiment was based on the idea that vitamin D has a dampening effect on an excessive and inappropriate immune response in many areas of your body, so they figured this was likely to apply to the thyroid as well. This turned out not to be the case, but what they did find was rather surprising.

First they created two groups of mice, one with vitamin D in their diet and the other with none. Even before they started their experiment they found that the vitamin D deficient mice had low levels of thyroxine (t4), meaning they were actually hypothyroid prone when the experiment was conducted. When the experiment was performed, vitamin D lacking mice did not have an excessive immune response as expected. Rather, they developed persistent hyperthyroidism because their thyroid glands were less able to withstand the stress of the experiment and were more sensitive to the autoimmune antibodies that both sets of mice were being exposed to. Simply put, a lack of vitamin D makes your thyroid more susceptible to injury that could result in hyperthyroidism.

While this is an animal study, the findings are important. First, it means that a lack of vitamin D contributes to the possibility of low thyroid. Second, it means that many irritants are likely to aggravate your thyroid to a greater extent if you lack vitamin D. For example, there are many chemical irritants in the environment that irritate your thyroid gland, such as perchlorate and fluoride. If you lack vitamin D you are more likely to be adversely affected by them.

This may be part of the reason that so many people feel metabolically worse and gain weight as the winter months move along. It is simple to make sure you take some extra D in the winter and doing so may help you keep your metabolism and thyroid from suffering the winter blues. Courtesy Wellness Resources.


Rituximab May Ease Fatigue in Sjogren's Syndrome By David Douglas

NEW YORK (Reuters Health) Nov 06 - Results of a pilot study suggest that rituximab may reduce fatigue in patients with Sjogren's syndrome and thus may improve quality of life, UK researchers report in the November issue of the Annals of the Rheumatic Diseases.

Dr. Paul Emery of Allerton Hospital, Leeds, and colleagues studied 17 patients with a fatigue score of more than 50 on a 100-mm visual analogue scale. They were randomized in a double-blind fashion to receive 2 infusions of rituximab 1 g or placebo. All patients also received oral and intravenous steroids.

At 6 months, 7 of the 8 patients receiving rituximab showed a greater than 20% improvement in the VAS for fatigue. This was true of only 5 of the 9 patients who had placebo.

Overall, there was a significant 36.8% improvement in fatigue VAS in the rituximab group compared to a non-significant 17.9% improvement in the placebo group. General health was also significantly improved in the active treatment group, but not in the placebo group.

There was also a significant difference in measures of social functioning and a trend towards improved mental health scoring in the rituximab group.

Commenting on the findings, Dr. Emery told Reuters Health that "this was the first randomized controlled trial in Sjogren's syndrome to show benefit, in particular a significant improvement in fatigue, a major issue for patients. This pilot study will now be followed by a more definitive study."

Ann Rheum Dis 2008;67:1541-1544.

IODINE AND SJOGREN'S SYNDROMEWe encourage - especially in darker and colder seasons - the use of iodine supplementation. This need is increased with fluoridated municipal water supplies and use of fluoride based drugs in the antibiotic, antidepressant, anticholesterol and antiosteoporosis drugs et al. We also encourage the proper use of selenomethionine in the support of proper thyroid function.

Thyroid dysfunction in primary Sjogren's syndrome: a long-term followup study.
D'Arbonneau F, Ansart S, Le Berre R, Dueymes M, Youinou P, Pennec YL.

Arthritis Rheum. 2003 Dec 15;49(6):804-9.

"OBJECTIVE: To evaluate the prevalence of thyroid dysfunction and related autoantibodies in patients with primary Sjogren's syndrome (pSS), and to determine whether these abnormalities develop over time. METHODS: pSS patients (n = 137) and controls (n = 120) were investigated for thyroid dysfunction and for the presence of anti-thyroid peroxidase antibody (anti-TPO) and antithyroglobulin antibody (ATG). Followup time for patients was 1-16 years, and 72 of the 120 controls were reevaluated 3 years after initial evaluation. RESULTS: Thyroid disease was more frequent in the pSS patients than in the controls (30% versus 4%; P < 10(-4)), as were anti-TPO and ATG (11% versus 3%; P < 0.02, and 3% versus 1%, not significant). Ten of 107 euthyroid pSS patients dropped out of the study, and thyroid dysfunction became apparent at followup in 12 of the remaining 97. Most of the patients with thyroid-related autoantibodies at entry developed autoimmune thyroid disease thereafter. CONCLUSION: Thyroid dysfunction is frequent in pSS patients, and those prone to develop thyroid disorders are identified by thyroid-related autoantibodies, or by rheumatoid factor and anti-Ro/SSA activity."

Thyroid disease in primary Sjogren syndrome. Study in a series of 160 patients.
Ramos-Casals M, Garcia-Carrasco M, Cervera R, Gaya J, Halperin I, Ubieto I, Aymami A, Morla RM, Font J, Ingelmo M.

Medicine (Baltimore). 2000 Mar;79(2):103-8.

"We studied 160 consecutive patients (147 female and 13 male) with primary Sjogren syndrome (SS) to determine the prevalence and clinical significance of thyroid disease in a large series of patients with primary SS from our unit and to compare the prevalence and significance with those in 75 individuals without SS from a primary care center. Serum levels of thyroid hormones (free thyroxine, triiodothyronine, and thyroid-stimulating hormone) and autoantibodies against thyroglobulin (TgAb) and thyroid peroxidase (TPOAb) were measured in all SS patients and in 75 control patients. Fifty-eight (36%) of the 160 patients with primary SS had evidence of thyroid disease. Autoimmune thyroid disease (ATD) was diagnosed in 32 (20%) patients and nonautoimmune thyroid disease (NATD) in 26 (16%). No significant differences were found when these prevalences were compared with those in control patients. On the other hand, comparing those patients with altered hormonal profiles, patients with NATD showed mainly hyperthyroidism (10/17, 59% versus 2/20, 10% in patients with ATD, p = 0.001). Finally, when clinical and immunologic manifestations of SS were analyzed in patients with and without thyroid disease, respectively, we found that patients with thyroid disease had a higher prevalence of female gender (98% versus 88%, p = 0.03), antiparietal cell autoantibodies (33% versus 12%, p = 0.002), TgAb (30% versus 5%, p < 0.001), and TPOAb (40% versus 5%, p < 0.001). In conclusion, thyroid disease occurred in more than one-third of patients with primary SS; the main cause was ATD, which was present in 20% of the patients studied. We note that no significant differences were observed when the prevalence of thyroid disease (either ATD or NATD) was compared with that in a control group of similar age and gender. Our results indicate that middle-aged women (with or without SS) should be screened periodically for thyroid function."

Autoimmune thyroid disease in primary Sjogren's syndrome.
Perez B, Kraus A, Lopez G, Cifuentes M, Alarcon-Segovia D.

Am J Med. 1995 Nov;99(5):480-4.

"PURPOSE: To evaluate the prevalence of autoimmune thyroid disease and thyroid dysfunction in patients with primary Sjogren's syndrome. PATIENTS AND METHODS: Thyroid function of 33 patients with primary Sjogren's syndrome was clinically and biochemically evaluated. Thyroid hormones and autoantibodies against thyroid peroxidase, thyroglobulin, and thyroid hormones were measured. RESULTS: Autoimmune thyroid disease and thyroid dysfunction were found in 15 cases (45%): autoimmune thyroiditis in 8 (24%); autoimmune hyperthyroidism in 2 (6%); and reversible iodine-induced hypothyroidism in the remaining 5 (15%). One or more of the evaluated autoantibodies were detected in 8 euthyroid patients (24%). Overall, the prevalence of autoantibodies against thyroid peroxidase, thyroglobulin, thyroxine, and triiodothyronine was 45%, 18%, 42%, and 36%, respectively. CONCLUSIONS: The high prevalence of autoimmune thyroid disease and thyroid dysfunction found in primary Sjogren's syndrome, using sensitive immunologic and thyroid function tests, suggest that both diseases are more frequently associated than it was previously thought, and should be sought clinically and by laboratory tests in all patients with primary Sjogren's syndrome."

Old News Makes the Rounds Again

I'm slowly updating my original web site that went on-line in the early 1990s. I'm working on it a few pages at a time. I do hope to have some help from two students at one of my colleges very soon.

While updating I found this news from early 2005. I'm sure it was known well before that time. Now in 2008, are we there yet. Instant replay yes, but where was implementation back in the day?

D. Mail 3.8.05 "VITAMIN D CAN REDUCE PROSTATE RISK"
A new study reveals Vitamin D cuts a man's risk of prostate cancer by almost half. Researchers in Boston analysed blood & found men with the highest vit D had a 45% less risk of prostate cancer. They believe vit D inhibits cell growth & has anti-cancer properties. Vit D is lower in older men who are most prone to prostate cancer. The recommended daily amount of vit D is 400 iu but some experts think that is low.


And today we learn that this remarkable (fat soluable) vitamin might protect from low level radiation.

Our center offers high quality, high dose Vitamin D in several potencies. All profits help support our work.

Sunday, November 9, 2008

Medicaid Reduction in Service as Bush Prepares to Leave Office.

The new regulation jeopardizes community-based health services, including screening, diagnostic and dental services for children, as well as lab and ambulance services.

In line with the current administration's plans to issue, or relax, many economic, environmental, health and safety rules before they leave office on Jan. 20, this impact on the poor is a political favor now for a surge in costs later as illness rates rise and insurance payments fail to meet cost.

Keep in mind that members of Congress did little to address this sweeping change, so hope they will re-visit the issue in January.
November 8, 2008
New U.S. Rule Pares Outpatient Medicaid Services
By ROBERT PEAR
WASHINGTON — In the first of an expected avalanche of post-election regulations, the Bush administration on Friday narrowed the scope of services that can be provided to poor people under Medicaid’s outpatient hospital benefit.

Public hospitals and state officials immediately protested the action, saying it would reduce Medicaid payments to many hospitals at a time of growing need.

The new rule conflicts with efforts by Congressional leaders and governors to increase federal aid to the states for Medicaid as part of a new economic action plan.

President-elect Barack Obama has endorsed those efforts. At a news conference on Friday, he said that legislation to stimulate the economy should include “assistance to state and local governments” so they would not have to lay off workers or increase taxes.

In a notice published Friday in the Federal Register, the Bush administration said it had to clarify the definition of outpatient hospital services because the current ambiguity had allowed states to claim excessive payments.

“This rule represents a new initiative to preserve the fiscal integrity of the Medicaid program,” the notice said.

But John W. Bluford III, the president of Truman Medical Centers in Kansas City, Mo., said: “This is a disaster for safety-net institutions like ours. The change in the outpatient rule will mean a $5 million hit to us. Medicaid accounts for about 55 percent of our business.”

Alan D. Aviles, the president of the New York City Health and Hospitals Corporation, the largest municipal health care system in the country, said: “The new rule forces us to consider reducing some outpatient services like dental and vision care. State and local government cannot pick up these costs. If anything, we expect to see additional cuts at the state level.”

Carol H. Steckel, the commissioner of the Alabama Medicaid Agency, said the rule would reduce federal payments for outpatient services at two large children’s hospitals, in Birmingham and Mobile.

Richard J. Pollack, the executive vice president of the American Hospital Association, said these concerns were valid.

“The new regulation,” Mr. Pollack said, “will jeopardize important community-based services, including screening, diagnostic and dental services for children, as well as lab and ambulance services.”

Herb B. Kuhn, the deputy administrator of the Centers for Medicare and Medicaid Services, defended the rule.

“We are not trying to deny services,” Mr. Kuhn said. “We want to pay for them more accurately and appropriately. Payments for some services were way higher than they should be.”

The rule narrows the definition of outpatient hospital services to exclude those that could be provided and covered outside a hospital.

In May, the White House said it wanted to avoid the rush of “midnight regulations” that had occurred at the end of other administrations. But Bush administration officials said this week that they still intended to issue, or relax, many economic, environmental, health and safety rules before they leave office on Jan. 20.

Medicaid, financed jointly by the federal government and the states, provides health insurance to more than 50 million low-income people. Services can often be billed at a higher rate if they are performed in the outpatient department of a hospital rather than in a doctor’s office or a free-standing clinic. Hospitals generally have higher overhead costs.

Matt D. Salo, a health policy specialist at the National Governors Association, said, “The new rule is consistent with the administration’s effort to squeeze, shrink and flatten Medicaid spending.”

In a recent letter, the governors urged Congress to increase the federal share of Medicaid for at least two years. With state tax revenues plunging, many governors are considering cuts in Medicaid and other programs. Such cuts, they say, would further depress economic activity.

Ann Clemency Kohler, the executive director of the National Association of State Medicaid Directors, said: “The new rule is a pretty sweeping change from longtime Medicaid policy. Since the beginning of the program, states have been allowed to define hospital outpatient services. We have to question why the rule is being issued now, three days after the election, with a new administration coming in.”

The rule was proposed in September 2007. It takes effect on Dec. 8, six weeks before Mr. Bush leaves office.

Ms. Kohler said the rule would cut “money going to the states, to safety net providers, at a time when states are really being stressed.”

“More and more people are coming onto Medicaid,” she said. “People are losing their jobs and running out of unemployment benefits. Some employers can no longer afford to provide health insurance to their workers.”

In the last 18 months, Congress has imposed moratoriums on six other rules that would have cut Medicaid payments. But the administration says Congress did not block the rule issued on Friday.

Larry S. Gage, the president of the National Association of Public Hospitals, said, “We will urge Congress to extend the moratorium to this rule, and we will ask the Obama administration to withdraw it.”

Copyright 2008 The New York Times Company

And in other news we find Big Pharma (one great group of very substantial contributions to 'W') being cited for prolific Medicaid billing fraud.

Kansas is suing to recover millions in over payment -
According to the lawsuit, the Medicaid program spent more $160 million on meds last year. And the suit alleges the price for a drug paid by the state, based on a fraudulently-reported Average Wholesale Price and other price indicators, often bears no relationship to the true price and can exceed 100 percent to 200 percent above the actual price.

One example cited - Dey reported an AWP of $44.10 for Ipratropium Bromide, yet the AG claims the drugmaker sold the same drug to retail pharmacists for $8.35 - a 355 percent difference. And Glaxo reported an AWP of $128.24 for Zofran, but charged $22.61- a 450 difference
.

Perhaps is the current administration would move to prosecute Big Pharma for the egregious activity the recovery would save Medicaid from current cuts. The FDA might be cleaned up a little at the same time, and don't they need an overhaul!

WARNING: I once blew the whistle on perpetrators of Medicare fraud involving Washington state. Instead of doing an accurate investigation, Mike Gregoire, husband of the the current governor and formerly with the Medicaid Fraud unit in the AGs office (at a time when his wife was AG), he feel into lock step with the typical bureaucratic cover-up: Protect the System First.

Fortunately my contacts at the Region X HHS OIG office was glad to take my data. DOJ was prosecuting the company I tried to report to Gregoire for insurance fraud in ten states.

The FEDS won this case and got a $372 million settlement.

Former state legislator Dave Schmidt did do a proper investigation, finding egregious errors by the state. He assisted me in regaining my status. DOH still is covering up. Mike and some DOH cronies continued the fraud by "loosing" legal documents and ignoring fact. Funny though that the AAG assigned to represent the state came out in favor of my facts and me. Former gov Gary Locke ignored the facts too and went so far as to cover up for DOH lies, at a time when he agreed to a request by a US Congressman to investigate. Locke refused to look at my eveidence. Locke and Mike's wife are law school grads and should know very well about due process and equal protection. I can't say for sure, but they went very far to attack the messenger here. And lost some recovery money as well. For shame.

Fraud has many faces.

Using more drugs, not less, for cancer

Anti-angiogenesis drugs haven’t been more successful than standard chemotherapy for cancer.

These drugs include Stutent, Gleevec and Avastin. All three have had serious problems in use and do little to prolong life or cure the disease in any significant manner.

These drugs are very expensive and if they must be used in combination with other chemotherapy is there hope for extended life, quality of life and a cure?

There are many treatment options for cancer. Most of the effective one are not in the media kit sent to oncologists or taught in medical schools.

There is much less spent on prevention. But here's a tip you might enjoy reading -
"The John Wayne Cancer Institute is a supporter of the Vita-Mix."
With the help of this wonderful invention, patients can more easily satisfy their goal of eating five servings of fruits and vegetables daily. The therapeutic antioxidants and phytochemicals in Vita-Mix whole food meals have shown to lower the risk of heart disease, cancer and other health problems.